Galectin Therapeutics’ Executive Chairman to Discuss Silent Epidemic and Company’s Role in Developing Treatments for NASH and Other Diseases at Robins Equity Research Roundup Conference

NORCROSS, Ga., Oct. 7, 2015 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that James Czirr, the Company’s Executive Chairman will present at the Robins Equity Research Roundup Conference taking place October 8-10, 2015. Mr. Czirr’s presentation, entitled Developing A Therapy for a Silent Epidemic – What Galectin Therapeutics is doing to Develop Treatments for NASH with Liver Cirrhosis and Other Unmet Medical Needs is scheduled for Friday, October 9 at 11:15 a.m. Pacific time. The Robins Equity Research Roundup is presented by Catalyst Research Management Group.An audio replay of Mr. Czirr’s presentation will be posted to the Investor Relations section of the company’s website the following week.The conference is being held at Skamania Lodge, in the Cascade Range Gorge above the Columbia River. The Robins Equity Research Roundup is a small-cap investor conference focused on introducing new and interesting company equities and their managements to clients and potential shareholders. The audience will include investors and brokers from the region as well as professional money managers from different parts of the country.About Galectin TherapeuticsGalectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for GR-MD-02 will lead to an additional therapy for the treatment of psoriasis as well as the first therapy for the treatment of fatty liver disease with cirrhosis. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, that Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of GR-MD-02 or any of its other drugs in development for the treatment of psoriasis, fatty liver disease with cirrhosis or other diseases. The Company’s current clinical trials and any future clinical studies may not produce positive results in a timely fashion, if at all, and could prove time consuming and costly. Plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies. There are a number of drugs available for the treatment of psoriasis, which may affect both the approval of GR-MD-02 for the treatment of psoriasis and the subsequent marketing of it. Regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.Jack Callicutt, Chief Financial Officer
(678) 620-3186

Kim Golodetz
(212) 838-3777